Immunomodulatory preparations and related methods

Abstract

A composition and corresponding method for immunomodulation. The composition comprises an emulsion formed from a pharmaceutically acceptable carrier mixed with active ingredients. The pharmaceutically acceptable carrier comprises 15-85% by weight of the composition. The active ingredients include an effective amount of hemp extract to provide a source of exogenous cannabinoids, an effective amount of a cannabinoid enhancer to inhibit cannabinoid hydrolases, an effective amount of a fatty acid amide to enhance cannabinoid activity via the entourage effect, an effective amount of kava extract to reduce anxiety, and an effective amount of an alkaloid to increase the bioavailability of one or more of the active ingredients.

Claims

1. A composition for treating SARS-CoV-2 infection by targeting cannabinoid receptors, The composition comprises an emulsion formed from a pharmaceutically acceptable carrier mixed with an active ingredient, wherein the pharmaceutically acceptable carrier is present in an amount of 15 to 85% by weight of the composition, and the active ingredient is A hemp extract in an amount of 5 to 40% by weight of the composition, for providing a source of exogenous cannabinoids. A cannabinoid enhancer containing oleamide for inhibiting cannabinoid hydrolase, wherein the cannabinoid enhancer is present in an amount of 1.5 to 6% by weight of the composition, and the cannabinoid enhancer is metabolized by hepatic enzymes. To enhance cannabinoid activity via the entourage effect, a fatty acid amide (excluding oleamide) in an amount of 1.5 to 11% by weight of the composition, To alleviate anxiety, kava extract in an amount of 6.0 to 35% by weight of the composition, and Alkaloids in an amount of 0.2 to 3% by weight of the composition to enhance the bioavailability of one or more of the active ingredients. A composition containing the following:

2. The aforementioned pharmaceutically acceptable carrier is a medium-chain triglyceride. The aforementioned fatty acid amide is palmitoylethanolamide (PEA), The aforementioned alkaloid is piperine. The composition according to claim 1.

3. The composition according to claim 1, wherein at least a portion of the active ingredient is at least partially encapsulated with lecithin, and the lecithin is present in an amount of 0.2 to 3% by weight of the composition.

4. The composition according to claim 3, wherein at least a portion of the active ingredient comprises the alkaloid.

5. The composition according to claim 1, wherein the hemp extract comprises at least one of cannabidiol (CBD), tetrahydrocannabinol (THC), cannabigerol, cannabinol, and terpene.

6. The composition according to claim 5, wherein the CBD constitutes 99.5% of the cannabinoids in the hemp extract.

7. The composition according to claim 5, wherein the hemp extract comprises CBD, and the CBD is either whole-spectrum CBD or a CBD isolate.

8. The composition according to claim 7, wherein the CBD is a CBD isolate and the hemp extract is in an amount of 8% by weight of the composition.

9. The composition according to claim 7, wherein the hemp extract contains β-caliphyllene in an amount of 0.005 to 0.03% by weight of the composition.

10. A method for preparing a composition for treating SARS-CoV-2 infection, wherein the method is: A step of forming a solution by combining a pharmaceutically acceptable carrier with an active ingredient, wherein the active ingredient is A hemp extract in an amount of 5 to 40% by weight of the composition, for providing a source of exogenous cannabinoids. A cannabinoid enhancer containing oleamide for inhibiting cannabinoid hydrolase, wherein the cannabinoid enhancer is present in an amount of 1.5 to 6% by weight of the composition, and the cannabinoid enhancer is metabolized by hepatic enzymes. To enhance cannabinoid activity via the entourage effect, a fatty acid amide (excluding oleamide) in an amount of 1.5 to 11% by weight of the composition, and Alkaloids in an amount of 0.2 to 3% by weight of the composition to enhance the bioavailability of one or more of the active ingredients. The steps of forming the solution, including A step of cooling the aforementioned solution to a temperature below 60°C. The steps include adding kava extract to the cooled solution, and The step of forming the composition by further cooling the cooled solution to a temperature below 0°C. A method that includes this.

11. The method of claim 10, wherein the step of combining the pharmaceutically acceptable carrier with the active ingredient further comprises heating the pharmaceutically acceptable carrier to a temperature of at least 80°C before combining the active ingredient with the pharmaceutically acceptable carrier.

12. The method according to claim 11, further comprising the step of combining the pharmaceutically acceptable carrier with the active ingredient, by dissolving lecithin in the pharmaceutically acceptable carrier when the temperature of the pharmaceutically acceptable carrier is 80°C to 90°C to form a first intermediate solution.

13. The method according to claim 12, further comprising the step of combining the pharmaceutically acceptable carrier with the active ingredient, by dissolving the cannabinoid enhancer in the first intermediate solution when the temperature of the first intermediate solution is 70°C to 80°C to form a second intermediate solution.

14. The method according to claim 13, further comprising the step of combining the pharmaceutically acceptable carrier with the active ingredient, by dissolving the fatty acid amide in the second intermediate solution when the temperature of the second intermediate solution is 70°C to 80°C to form a third intermediate solution.

15. The method according to claim 14, further comprising the step of combining the pharmaceutically acceptable carrier with the active ingredient, by dissolving the alkaloid in the third intermediate solution when the temperature of the third intermediate solution is 70°C to 85°C, thereby forming a fourth intermediate solution.

16. The method according to claim 15, further comprising the step of combining the pharmaceutically acceptable carrier with the active ingredient by adding the hemp extract to the fourth intermediate solution when the temperature of the fourth intermediate solution is 70°C to 85°C to form the solution.

17. The method according to claim 16, further comprising emulsifying the solution.

18. The method according to claim 16, wherein the further cooling step is carried out over a period of 5 to 10 hours, and the addition of the kava extract to the cooled solution further comprises emulsifying the cooled solution.

19. The method according to claim 10, wherein the hemp extract is a cannabidiol isolate, and the method further comprises adding β-caliphyllene to the cooled solution.

Images